Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Immunity enhancing agent, inactivated vaccine, and preparation method thereof

An immune enhancer and inactivated vaccine technology, applied in the field of biopharmaceuticals, can solve the problems of large side effects and external stimulation of pigs, and achieve the effects of low cost, enhanced immune effect, and short immune window period

Inactive Publication Date: 2014-12-10
JIANGSU ACAD OF AGRI SCI +1
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The existing porcine circovirus inactivated vaccine has relatively large side effects, and needs to be immunized 3 weeks after immunization, which brings serious external stimulation to the pig body

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Immunity enhancing agent, inactivated vaccine, and preparation method thereof
  • Immunity enhancing agent, inactivated vaccine, and preparation method thereof
  • Immunity enhancing agent, inactivated vaccine, and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] Example 1 Influence of immune enhancer 1 on the immune efficacy of inactivated foot-and-mouth disease vaccine

[0038] 1. Experimental materials

[0039] The inactivated porcine type O foot-and-mouth disease virus liquid (the strain is 98 strains of porcine type O foot-and-mouth disease virus from Myanmar) was inactivated by diethyleneimine, and the content of 146s was 4ug / mL.

[0040] Healthy susceptible piglets aged 6-7 weeks, liquid-phase blocking ELISA antibody titer ≤ 1:8.

[0041] 2. Preparation of vaccine:

[0042] Immunopotentiator 1 contains 2 mg / mL MPL, 20 mg / mL MDP, and 0.4 mg / mL β-glucan, and the solvent is distilled water.

[0043] An aqueous phase solution was prepared by mixing the immune enhancer 1 with the inactivated porcine O-type foot-and-mouth disease virus liquid in a volume ratio of 1:3. The ISA206 and the aqueous solution were first placed at room temperature for about 30 minutes. Put ISA206 into the emulsification tank, put the aqueous solut...

Embodiment 2

[0058] Example 2 The effect of immune enhancer 2 on the immune efficacy of inactivated foot-and-mouth disease vaccine

[0059] 1. Experimental materials

[0060] The inactivated O-type swine foot-and-mouth disease virus liquid (the strain is 98 strains of porcine O-type FMD virus from Myanmar) was inactivated by diethyleneimine, and the content of 146s was 5.87ug / mL.

[0061] Healthy susceptible piglets aged 6-7 weeks, liquid-phase blocking ELISA antibody titer ≤ 1:8.

[0062] 2. Preparation of vaccine:

[0063] Formulated immune enhancer 2. Immunopotentiator 2 contains 2 mg / mL MPL, 40 mg / mL MDP, and 0.4 mg / mL β-glucan, and the solvent is distilled water.

[0064] The immune enhancer 2 is mixed with the inactivated swine foot-and-mouth disease virus liquid in a volume ratio of 1:1 to obtain an aqueous phase solution. The ISA206 and the aqueous solution were first placed at room temperature for about 30 minutes. Put ISA206 into the emulsification tank, put the aqueous solu...

Embodiment 3

[0079] Example 3 Immunopotentiator 3 Influence on the immune efficacy of inactivated foot-and-mouth disease vaccine

[0080] 1. Experimental materials

[0081] The inactivated porcine type O foot-and-mouth disease virus liquid (the strain is 98 strains of porcine type O foot-and-mouth disease virus from Myanmar) was inactivated by diethyleneimine, and the content of 146s was 5.87ug / mL.

[0082] Healthy susceptible piglets aged 6-7 weeks were tested with a liquid-phase blocking ELISA kit for foot-and-mouth disease (Lanzhou Veterinary Research Institute) to obtain a liquid-phase blocking ELISA antibody titer of ≤1:8.

[0083] 2. Preparation of vaccine:

[0084] Immunopotentiator 3 contains 0.1 mg / mL MPL, 2 mg / mL MDP, and 0.1 mg / mL β-glucan in distilled water.

[0085] The immune enhancer 3 is mixed with the inactivated swine foot-and-mouth disease virus liquid in a volume ratio of 1:1 to obtain an aqueous solution. The ISA206 and the aqueous solution were first placed at ro...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
antibody titeraaaaaaaaaa
antibody titeraaaaaaaaaa
Login to View More

Abstract

The invention provides an immunity enhancing agent, an inactivated vaccine, and a preparation method thereof. The invention relates to the field of biopharmaceutical. The immunity enhancing agent comprises 0.1-21mg / mL of monophosphoryl lipid A, 1.5-125mg / mL of muramyl dipeptide, and 0.7-4.5mg / mL of beta-glucan. The invention also provides the inactivated vaccine comprising the immunity enhancing agent, and a preparation method of the inactivated vaccine. According to the invention, the immunity enhancing agent is mixed with an inactivated antigen solution, such that a water-phase solution is obtained; and the water-phase solution is mixed with an oil-phase solution, such that the inactivated vaccine is obtained. According to the immunity enhancing agent provided by the invention, with a synergetic effect of the components, body immunity level can be improved, and immune response to antigen can be improved, such that antibody level after immunization can be increased, immune window period can be shortened, and vaccine immunization effect can be enhanced. According to the inactivated vaccine comprising the immunity enhancing agent, antibody level after immunization is high, a protection period is long, and immunization window period is short.

Description

technical field [0001] The invention relates to the field of biopharmaceuticals, in particular to an immune enhancer, an inactivated vaccine and a preparation method thereof. Background technique [0002] Foot and mouth disease (Foot and mouse disease, FMD) is caused by foot and mouth disease virus (Foot-and-Mouth Disease Virus, FMDV), an acute, hot and highly contact infectious disease that occurs in artiodactyls. At present, this disease is prevalent in many countries in the world, causing great economic losses to animal husbandry. Moreover, the recessive infection of the disease can reduce the production capacity of sick animals and cause huge economic losses. It is listed as the first type of animal disease in my country. [0003] At present, the international community mainly adopts two measures for the prevention and control of foot-and-mouth disease: emergency culling and immunization. In our country, compulsory immunization is mainly adopted, while the policy of bl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/39A61K9/107A61K39/135A61K39/12A61K39/215A61P31/20A61P31/14
Inventor 陈瑾郑其升侯立婷李鹏成于晓明徐海侯继波
Owner JIANGSU ACAD OF AGRI SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com